亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

16052-06-5 EPPS 韻邦生產 匯百試劑

 
 
單價 面議對比
詢價 暫無
發貨 湖南長沙市付款后3天內
品牌 匯百試劑
過期 長期有效
更新 2021-08-13 15:18
 

湖南韻邦生物醫藥有限公司

企業會員第8年
資料未認證
保證金未繳納
詳細說明
中文名稱:4-(2-羥乙基)-1-哌嗪丙磺酸 
CAS號:16052-06-5
中文別名:HEPPS; 4-羥乙基哌嗪丙磺酸; 4-(2-羥乙基)-1-哌嗪丙磺酸
英文名稱:3-(4-(2-Hydroxyethyl)piperazin-1-yl)propane-1-sulfonic acid
英文別名:3-[4-(2-Hydroxyethyl)-1-piperazine]propanesulfonic acid; 4-(2-Hydroxyethyl)-1-piperazinepropanesulfonic acid; HEPPS N-(2-Hydroxyethyl)piperazine-N-3-propanesulfonic acid; N-(2-Hydroxyethyl)-N-(3-sulfopropyl)-piperazine; HEPPS, ULTROL Grade; HEPPS~4-(2-Hydroxyethyl)-1-piperazinepropanesulphonic acid; aEPPS; HEPPS
EINEC:240-198-8
分子式:C9H20N2O4S
分子量:252.3311
舉報收藏 0評論 0
更多>本企業其它產品
7365-45-9 HEPES 韻邦工廠 匯百試劑 4432-31-9 MES 韻邦生產 匯百試劑 145224-94-8 MES monohydrate 韻邦 71119-23-8MES sodium salt 韻邦工廠 7365-44-8 TES 韻邦生產 匯百試劑 7365-82-4 ACES 韻邦生產 匯百試劑 5625-37-6 PIPES 韻邦工廠 匯百試劑
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |